Abstract
FHIT (fragile histidine triad) is a tumor-suppressor gene located at chromosome band 3p14.2. The genomic locus, which is greater than 1 Mb, contains 10 small exons that make up the 1.1-kb FHIT cDNA. The coding region starts in exon 5 and stops in exon 9, producing a 16.8-kDa cytoplasmic protein. The FHIT locus contains the hereditary renal cell carcinoma (RCC) t(3;8) translocation, and also encompasses the FRA3B common fragile region (for review, 1). Numerous studies have proven that the FHIT gene is inactivated by deletions in both primary tumors and cell lines derived from head and neck, stomach, lung, and kidney cancers (2–6). Since FHIT is inactivated in so many cancers, it is essential to learn its normal function and analyze how the loss of its function contributes to the progression and development of cancer. For example, an early event in the lungs of a smoker is breakage at the FHIT locus, causing a reduced or absent FHIT protein expression in the preneoplastic lesions. Compensation for the functional loss of FHIT via a recombinant, nonfragile FHITgene may prove therapeutically useful (7,8). Our studies have also shown that the FHIT gene is altered or absent in the majority of transitional-cell carcinoma (TCC) cases of the bladder examined (9). Through the utilization of molecular techniques such as those described here, FHIT alterations may be detected in an early stage of cancer, and thus prove to be a useful diagnostic tool to prevent cancer progression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Druck, T., Berk, L., and Huebner, K. (1998) FHITness and cancer. Oncol. Res.10, 341–345.
Mao, L., Fan, Y., Lotan, R., and Hong, W. (1996) Frequent abnormalities of FHIT, acandidate tumor suppressor gene, in head in neck cancer. Cancer Res.56, 5128–5131.
Virgilio, L., Shuster, M., Gollin, S., Veronese, M. L., Ohta, M., Huebner, K., and Croce, C. M. (1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA93, 9770–9775.
Baffa, R., Veronese, M. L., Santoro, R., Mandes, B., Palazzo, J., Rugge, M., Santoro, E., Croce, C. M., and Huebner, K. (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res.57, 4708–4714.
Fong, K., Biesterveld, T., Virmani, A., Wistuba, I., Sekido, Y., Alder, S. A., Ahmadian, M., Ong, S. T., Rassool, F. V., and Zimmerman, P. V. (1997) FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and pre-neoplasticbronchial lesions and are associated with cancer related FHIT cDNA splicing aberrations. Cancer Res.57, 2256–2267.
Velickovic, M., Delahunt, B., and Grebe, S. (1999) Loss of heterozygosity at 3p14.2 in clear cell renal carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res.59, 1323–1326.
Sozzi, G., Tornielli, S., Tagliabue, E., Sard, L., Pezzella, F., Pastorino, U., Minoletti, F., Pilotti, S., Ratecliffe, C., Veronese, M. L., Goldstraw, P., Huebner, K., Croce, C.M., and Pierotti, M. A. (1997) Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res.57, 5207–5212.
Ji, L., Fang, B., Yen, N., Fong, K., Minna, J. D., and Roth, J. A. (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression Cancer Res.59, 3333–3339.
Baffa, R., Gomella, L. G., Vecchione, A., Bassi, P., Mimori, K., Sedor, J., Calviello, C. M., Gardiman, M., Minimo, C., Strup, S. E., McCue, P. A., Kovatich, A. J., Pagano, F., Huebner, K., and Croce, C. M. (2000) Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am. J. Pathol.156, 419–424.
Huebner, K., Sozzi, G., Brenner, C., Pierotti, M., and Croce, C. M. (1999) Fhit loss in lung cancer. Adv. Oncol.15, 3–9.
Sambrook, J., Fritch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Ohta, M., Inoue, H., Cotticelli, M., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C., and Huebner, K. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell84, 587–597.
Kwok, S. and Higuchi, R. (1989) Avoiding false positives with PCR. Nature339, 237–238.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Baffa, R., Calviello, C.M., Druck, T., Gomella, L.G. (2001). Analyzing the FHIT Gene by RT-PCR, Western Blotting, and Immunohistochemistry. In: Mydlo, J.H. (eds) Renal Cancer. Methods in Molecular Medicine, vol 53. Humana, Totowa, NJ. https://doi.org/10.1385/1-59259-144-2:081
Download citation
DOI: https://doi.org/10.1385/1-59259-144-2:081
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-0-89603-828-8
Online ISBN: 978-1-59259-144-2
eBook Packages: Springer Protocols